Sophiris Bio Inc. Reports First Quarter Financial Results and Recent Key Operational Highlights
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, CA and VANCOUVER, April 30, 2013 -- /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a urology company developing a clinical-stage, targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the first quarter ended March 31, 2013.
Help employers find you! Check out all the jobs and post your resume.
SAN DIEGO, CA and VANCOUVER, April 30, 2013 -- /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a urology company developing a clinical-stage, targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the first quarter ended March 31, 2013.
Help employers find you! Check out all the jobs and post your resume.